Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Albumins
Antineoplastic Combined Chemotherapy Protocols
Female
Fluorouracil
Gastrointestinal Neoplasms
Glucuronosyltransferase
Humans
Leucovorin
Male
Maximum Tolerated Dose
Middle Aged
Paclitaxel
Patient Safety
Polymorphism, Genetic
Treatment Outcome

authors with profiles

Mark Kozloff
Theodore Karrison
Blase Polite
Hedy Kindler
Andrea Amico